Velcade

Showing 15 posts of 22 posts found.

janssen_latest_logo_on_sign

NICE recommends Janssen’s Darzalex myeloma combo

March 12, 2019
Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma

Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …

Janssen Velcade

NICE recommends Velcade for MCL, and three diabetes drugs

December 23, 2015
Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL).  In the …

kyprolis_amgen

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …

Takeda oncology

Challenges in oncology R&D

November 18, 2015
Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Takeda oncology

Takeda in Velcade patent blow

August 25, 2015
Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib

Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …

Velcade image

J&J blood cancer drug gets UK launch

March 25, 2015
Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl

Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …

FDA in Novartis cancer drug U-turn

February 24, 2015
Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma

The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …

J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

Janssen image

Patient access schemes ‘lack transparency’

December 12, 2014
Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme

Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …

Takeda image

Takeda eyes new drug licences following positive blood cancer studies

December 11, 2014
Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology

Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …

Velcade image

NICE approves Velcade

March 21, 2014
Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma

NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …

janssen image

Janssen/Pharmacyclics gain FDA nod for Imbruvica

November 14, 2013
Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade

The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …

Velcade image

NICE needs more Velcade data

November 12, 2013
Sales and Marketing NHS, NICE, Velcade, eric low

NICE has slowed the progress of Janssen Cilag’s Velcade towards becoming an NHS treatment for multiple myeloma by asking the …

jj_2johnson_and_johnson

Johnson & Johnson posts strong Q3 results

October 16, 2013
Sales and Marketing J&J, JJ, Q3, Velcade, results

Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …

Celgene image

Celgene’s multiple myeloma pill launched in UK

August 15, 2013
Sales and Marketing Celgene, Velcade, low, myeloma

Celgene’s new oral blood cancer drug pomalidomide has been launched in the UK and Ireland as a third line treatment …

The Gateway to Local Adoption Series

Latest content